Skip to main content
Premium Trial:

Request an Annual Quote

Thomson Reuters, NuMedii Ink Partnership Around Drug Repurposing

Premium

Thomson Reuters and NuMedii this week announced a partnership that will pair NuMedii's underlying informatics technology with curated drug and disease information and systems biology expertise from Thomson Reuters for use in identifying new applications for existing drugs.

Specifically, NuMedii will combine content from Thomson Reuters MetaCore and Integrity repositories with its technology — based on machine learning, pattern matching, and network biology algorithms — and use it to find FDA-approved drugs or discontinued development compounds that are appropriate for repurposing.

"This unique partnership allows NuMedii access to an unparalleled source of knowledge from Thomson Reuters, enabling us to turbo-charge our search and discovery of new applications for existing therapies," according to Gini Deshpande, founder and chief executive officer of NuMedii.

It's also an opportunity to “combine the leading information sources available with novel analytics, data integration, and biomedical expertise in a way that has not been done before outside of a laboratory environment,” Joe Donahue, senior vice president of Thomson Reuters Life Sciences, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more